Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151668 | 0.92 | TSHR (0.48) | TSHRLCKSIGMAR1ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL27737564 | 0.88 | TSHR (0.50) | TSHRLCKSIGMAR1ALDH1A1TDP1 | |
| Acetic Acid SCHEMBL5157261 | 0.87 | PAOX (0.40) | TSHRLCKSIGMAR1ALDH1A1CYP1A2 | |
| SCHEMBL151280 | 0.84 | TSHR (0.57) | TSHRLCKALDH1A1TDP1CYP1A2 | |
| SCHEMBL64558 | 0.83 | — | — | |
| SCHEMBL23388983 | 0.83 | LCK (0.56) | TSHRLCKALDH1A1TDP1CYP1A2 | |
| SCHEMBL147519 | 0.82 | TSHR (0.62) | TSHRLCKALDH1A1TDP1CYP1A2 | |
| Hydrochloric Acid SCHEMBL10492840 | 0.81 | LCK (0.44) | TSHRLCKALDH1A1TDP1MAPK1 | |
| SCHEMBL11141675 | 0.78 | TSHR (0.56) | TSHRLCKPLA2G1BPLA2G2AKCNH2 | |
| SCHEMBL18755072 | 0.78 | TSHR (0.50) | TSHRLCKDRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023142167-A1 | CATIONIC LIPID ANALOG, AND COMPOSITION AND USE THEREOF | 广州立得生物医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| EP-2526149-B1 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORP (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9469710-B2 | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORPORATION (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150148489-A1 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-05-28 | — | — | US | disclosed |
| US-8735494-B2 | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORPORATION (JP) | 2014-05-27 | — | — | US | disclosed |
| US-20130085227-A1 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8344066-B2 | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORPORATION (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20120296041-A1 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2012-11-22 | — | — | US | disclosed |
| US-20120059112-A1 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS COMTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| CN-102361887-A | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORP | 2012-02-22 | — | — | CN | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | AVENTIS PHARMACEUTICALS INC. | 2003-08-14 | — | — | US | disclosed |
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| US-4196233-A | Process for coating inorganic substrates with carbides, nitrides and/or carbonitrides | CIBA-GEIGY CORPORATION (US) | 1980-04-01 | — | — | US | disclosed |
| US-4028142-A | ON IRON, BORON, SILICON ANDOR GROUP 4B TO 6B METALS BY DECOMPOSITION TO PRODUCE DIFFUSION LAYERS | CIBA-GEIGY CORPORATION (US) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203115-A1 | Novel quaternary ammonium compounds | SLC10A2, SLC10A1, ABCB11 | TSHR 3847/4885LCK 4017/4885SIGMAR1 932/4885 |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | SERPINC1, F2, F11 | TSHR 2219/4885LCK 4358/4885SIGMAR1 4736/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | TSHR 2972/4885LCK 4701/4885SIGMAR1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.